Literature DB >> 9466084

Calcium antagonists and cancer. Is there really a link?

L G Howes1, C T Edwards.   

Abstract

Recent publications have raised concerns about a possible link between calcium antagonist therapy and the development of cancer. Comparisons of the methodology and results of these studies with other studies where an association between calcium antagonist therapy and cancer has not been apparent suggests that the association is most likely to be due to selection bias or chance. Clinical and biochemical studies have not produced a consistent plausible mechanism for a causative link between calcium antagonists and the development of cancer. Further prospective data that will be available from long-term morbidity and mortality trials of the use of calcium antagonists in cardiovascular diseases will be of value in establishing the safety of these drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466084     DOI: 10.2165/00002018-199818010-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  30 in total

1.  Shanghai trial of nifedipine in the elderly (STONE).

Authors:  L Gong; W Zhang; Y Zhu; J Zhu; D Kong; V Pagé; P Ghadirian; J LeLorier; P Hamet
Journal:  J Hypertens       Date:  1996-10       Impact factor: 4.844

2.  Observational studies of drug safety.

Authors:  A M Walker; M J Stampfer
Journal:  Lancet       Date:  1996-08-24       Impact factor: 79.321

3.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.

Authors:  T Tsuruo; H Iida; M Nojiri; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

4.  Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study.

Authors:  L R Zacharski; T E Moritz; C M Haakenson; J F O'Donnell; H S Ballard; G J Johnson; Q S Ringenberg; R L Schilsky; M B Spaulding; K Tornyos
Journal:  Cancer Invest       Date:  1990       Impact factor: 2.176

5.  Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients.

Authors:  S Braun; V Boyko; S Behar; H Reicher-Reiss; A Shotan; Z Schlesinger; T Rosenfeld; A Palant; A Friedensohn; S Laniado; U Goldbourt
Journal:  J Am Coll Cardiol       Date:  1996-07       Impact factor: 24.094

6.  Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes.

Authors:  L Juntti-Berggren; O Larsson; P Rorsman; C Ammälä; K Bokvist; K Wåhlander; P Nicotera; J Dypbukt; S Orrenius; A Hallberg
Journal:  Science       Date:  1993-07-02       Impact factor: 47.728

7.  Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse.

Authors:  J M Taylor; R U Simpson
Journal:  Cancer Res       Date:  1992-05-01       Impact factor: 12.701

8.  Calcium channel blockers: potential antimetastatic agents.

Authors:  K V Honn; J M Onoda; C A Diglio; B F Sloane
Journal:  Proc Soc Exp Biol Med       Date:  1983-10

9.  Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.

Authors:  T Tsuruo; H Iida; K Naganuma; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

10.  High blood-pressure: a risk factor for cancer mortality?

Authors:  A R Dyer; J Stamler; D M Berkson; H A Lindberg; E Stevens
Journal:  Lancet       Date:  1975-05-10       Impact factor: 79.321

View more
  1 in total

1.  Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.

Authors:  Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.